Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients(257 views visite) Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Gasperi M, Prinster A, Vacca G, Pivonello C, Orefice G, Colao A, Morra VB
Keywords Parole chiave: Case-Control Study, Insulin-Like Growth Factor-Binding Protein-3, Multiple Sclerosis, Relapsing-Remitting, Secondary Progressive, Somatomedin Binding Protein 3, Adult, Article, Clinical Assessment Tool, Controlled Study, Disease Activity, Disease Course, Expanded Disability Status Scale, Female, Human, Major Clinical Study, Multiple Sclerosis Severity Scale, Priority Journal, Protein Blood Level, Secondary Progressive Multiple Sclerosis, Age Factors, Case-Control Studies, Insulin-Like Growth Factor Binding Protein 3, Middle Aged, Chronic Progressive, Severity Of Illness Index, Time Factors, Insulin-Like Growth Factor Binding Protein 3 Blood Physiology, Insulin-Like Growth Factor I Analysis Physiology, Chronic Progressive Blood Physiopathology, Relapsing-Remitting Blood Physiopathology,
Affiliations Affiliazioni: *** IBB - CNR ***
Neurology, Hermitage Capodimonte Hospital, Naples, Italy Department of Neurological Sciences, University 'Federico II', Naples, Italy SDN Foundation, Naples, Italy Biostructure and Bioimaging Institute, National Research Council, Naples, Italy Department of Health Science, University of Molise, Contrada Tappino, Campobasso, Italy Departments of Molecular and Clinical Endocrinology and Oncology, University 'Federico II', Naples, Italy
References Riferimenti: Roth, G.A., Spada, V., Hamill, K., Bornstein, M.B., Insulin-like growth factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue (1995) Brain Res Dev Brain Res, 88, pp. 102-10
Mc Morris, F.A., Smith, T.M., De Salvo, S., Furlanetto, R.W., Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development (1986) Proc Natl Acad Sci U S A, 83, pp. 822-826
Mason, J.L., Ye, P., Suzuki, K., D' Ercole, A.J., Matsushima, G.K., Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination (2000) J Neurosci, 20, pp. 5703-5708
Barres, B.A., Hart, I.K., Coles, H.S., Cell death in the oligodendrocyte lineage (1992) J Neurobiol, 23, pp. 1221-1230
Wilczak, N., Schaaf, M., Bredewold, R., Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis (1998) Neurosci Lett, 257, pp. 168-170
Torres-Aleman, I., Barrios, V., Berciano, J., The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis (1998) Neurology, 50, pp. 772-776
Wilczak, N., Ramsaransing, G.S., Mostert, J., Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis (2005) Mult Scler, 11, pp. 13-15
Poljakovic, Z., Zurak, N., Brinar, V., Growth hormone and insulin growth factor-I levels in plasma and cerebrospinal fluid of patients with multiple sclerosis (2006) Clin Neurol Neurosurg, 108, pp. 255-258
Hosback, S., Hardiman, O., Nolan, C.M., Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis (2007) Growth Horm IGF Res, 17, pp. 472-479
Poser, C.M., Paty, D.W., Scheinberg, L., New diagnostic criteria for multiple sclerosis: guidelines for research protocols (1983) Ann Neurol, 13, pp. 227-231
Oscarsson, J., Johannsson, G., Johansson, J.O., Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults (1997) Clin Endocrinol (Oxf), 46, pp. 63-68
Sonntag, W.E., Ramsey, M., Carter, C.S., Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging (2005) Ageing Res Rev, 4, pp. 195-212
Rensink, A.A., Gellekink, H., Otte-Höller, I., Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease (2002) Acta Neuropathol, 104, pp. 525-533
Lovett-Racke, A.E., Bittner, P., Cross, A.H., Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1)and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3) (1998) J Clin Invest, 101, pp. 1797-1804
Rudick, R., Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis? (2003) Mult Scler, 9, pp. 210-212
Yateman, M.E., Claffey, D.C., Cwyfan Hughes, S.C., Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production (1993) J Endocrinol, 137, pp. 151-159
Besset, V., Le Magueresse-Battistoni, B., Collette, J., Benahmed, M., Tumor necrosis factor alpha stimulates insulin-like growth factor binding protein 3 expression in cultured porcine Sertoli cells (1996) Endocrinology, 137, pp. 296-303
Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(206 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(284 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(422 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R, Gigli G, Casciaro S, Pellegrino T, Ragusa A * MR Contrast Agents(230 visite) Small Animal Imaging, 2011 Jul 8; 21(13): 2548-2555. Impact Factor:1.784 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(409 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote